Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Leases (2016 - 2026)

Ironwood Pharmaceuticals' Current Leases history spans 16 years, with the latest figure at $3.3 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 1.98% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 1.98% increase, with the full-year FY2025 number at $3.3 million, up 1.98% from a year prior.
  • Current Leases hit $3.3 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $3.2 million in the prior quarter.
  • Over the last five years, Current Leases for IRWD hit a ceiling of $3.3 million in Q4 2025 and a floor of $3.0 million in Q3 2022.
  • Historically, Current Leases has averaged $3.1 million across 5 years, with a median of $3.1 million in 2021.
  • Biggest five-year swings in Current Leases: skyrocketed 67.59% in 2021 and later fell 3.39% in 2022.
  • Tracing IRWD's Current Leases over 5 years: stood at $3.1 million in 2021, then dropped by 1.98% to $3.1 million in 2022, then increased by 1.99% to $3.1 million in 2023, then grew by 2.02% to $3.2 million in 2024, then rose by 1.98% to $3.3 million in 2025.
  • Business Quant data shows Current Leases for IRWD at $3.3 million in Q4 2025, $3.2 million in Q3 2025, and $3.2 million in Q2 2025.